2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Leukemia, Myeloid, Acute
4
Carcinoma, Non-Small-Cell Lung
3
Myelodysplastic Syndromes
2
Metastatic Solid Tumors
2
Melanoma
2
Solid Tumors
1
Recurrent Metastatic Non-Squamous Non Small Cell Lung Cancer
1
Recurrence
1
Prostate Cancer Patients Undergoing Radical Prostatectomy
1
Neoplasms
1
Neoadjuvant Treatment for Locally Advanced Cervical Cancer
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Hepatocellular
1
Cancer Pain
1
Breast Neoplasms
1
Breakthrough Pain
1
Biliary Tract Neoplasms
1
Advanced Malignant Neoplasm
1
Interventions
Fluorouracil
497
Bevacizumab
476
Oxaliplatin
449
Leucovorin
440
Irinotecan
408
Cetuximab
317
Capecitabine
317
pembrolizumab
142
Folfox protocol
129
Panitumumab
117
regorafenib
105
Colonoscopy
88
Nivolumab
81
IFL protocol
81
Drug Therapy
77
trifluridine tipiracil drug combination
73
Radiotherapy
66
HMPL-013
65
Blood Specimen Collection
52
Gemcitabine
49
Specimen Handling
46
Neoadjuvant Therapy
45
Standard of Care
44
Magnetic Resonance Spectroscopy
43
Biopsy
43
Chemotherapy, Adjuvant
41
Trifluridine
40
atezolizumab
38
Surveys and Questionnaires
38
Cyclophosphamide
38
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colorectal Neoplasms
×
Infusions, Intravenous
×
Clear all
NCT00399035
2016-12-28
HORIZON II
AstraZeneca
Phase 3
Completed
1,254 enrolled
14 charts